Turning Point Therapeutics, Inc. - Common stock (NQ:TPTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Turning Point Therapeutics, Inc. - Common stock

< Previous 1 2 Next >

Blue Chip Stocks In Focus: Bristol-Myers Squibb ↗

August 15, 2022

The company has grown earnings by more than 20% per year on average over the last five and ten years. This explosive growth has enabled the company to continue growing its dividend.

Via Talk Markets

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 27, 2022

Via Benzinga

Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission ↗

July 27, 2022

Turning Point Therapeutics (NASDAQ: TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter.

Via Benzinga

The 3 Best Market Sectors for the Second Half of 2022 ↗

July 27, 2022

Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into.

Via InvestorPlace

UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up ↗

June 25, 2022

Shockwave and UnitedHealth lead 5 stocks that are setting up or breaking out.

Via Investor's Business Daily

Analyst Ratings for Turning Point ↗

June 06, 2022

Within the last quarter, Turning Point (NASDAQ:TPTX) has observed the following analyst ratings:

Via Benzinga

Turning Point Inks Licensing Pact For Gastrointestinal Cancers Candidate ↗

May 05, 2022

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

June 06, 2022

Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.

Via Benzinga

69 Biggest Movers From Friday ↗

June 06, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...

Via Benzinga

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More ↗

June 05, 2022

Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.

Via Benzinga

The Acquisition of Turning Point Therapeutics By BMY- Bristol- Myers.

June 03, 2022

BMY - Bristol-Myers Squibb in a transaction that values Turning Point Therapeutics (NASDAQ:TPTX). Report at roughly $4.1 billion, Bristol-Myers Squibb

Via Best Stocks

Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher ↗

June 03, 2022

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 300 points on Friday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 03, 2022

Via Benzinga

Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump ↗

June 03, 2022

U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday.

Via Benzinga

40 Stocks Moving In Friday's Mid-Day Session ↗

June 03, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.

Via Benzinga

CrowdStrike (CRWD) Stock Dips Despite Earnings Beat ↗

June 03, 2022

CrowdStrike (CRWD) stock is falling on Friday despite a positive Q1 fiscal 2023 earnings report from the cybersecurity company.

Via InvestorPlace

TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics ↗

June 03, 2022

Turning Point Therapeutics (TPTX) stock is rocketing higher on Friday following news of a deal with Bristol-Myers Squibb (BMY).

Via InvestorPlace

Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May ↗

June 03, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday.

Via Benzinga

Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead? ↗

June 03, 2022

Bristol Myers is moving deeper into the targeted oncology space.

Via Investor's Business Daily

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 03, 2022

Via Benzinga

Expert Ratings for Turning Point ↗

May 20, 2022

Over the past 3 months, 4 analysts have published their opinion on Turning Point (NASDAQ:TPTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022 ↗

May 20, 2022

Upgrades

Via Benzinga

Turning Point Therapeutics Gets FDA Breakthrough Therapy designation For Repotrectinib ↗

May 10, 2022

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate Repotrectinib in Patients With One...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 13, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Turning Point Reveals Topline Data From Pivotal Repotrectinib Trial In Lung Cancer Setting ↗

April 13, 2022

Turning Point Therapeutics Inc (NASDAQ: TPTX)

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 04, 2022

Gainers Trevi Therapeutics (NASDAQ:TRVI) ...

Via Benzinga

FDA Clears Turning Point's IND For Elzovantinib + Aumolertinib Combo Regime In Lung Cancer Setting ↗

January 20, 2022

The FDA has signed off Turning Point Therapeutics Inc's (NASDAQ: TPTX) Investigational New Drug (IND) application for elzovantinib + aumolertinib combo therapy...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

January 14, 2022

During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗

December 07, 2021

Upgrades For CarMax Inc (NYSE:

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.